Publications

  1. Abbadessa D, Smurthwaite CA, et al. A Single-Cell Platform for Monitoring Viral Proteolytic Cleavage in Different Cellular Compartments. Biochem Insights. 2016 Sep 22;8(Suppl 2):23-31. doi: 10.4137/BCI.S30379. eCollection 2015
  2. Wolkowicz R. Narrowing the translational research gap: what needs to be done? Future Med Chem. 2015;7(14):1843-6. doi: 10.4155/fmc.15.123. Epub 2015 Sep 22.PubMed PMID: 26393393.
  3. Kim BJ, Hancock BM, et al. Bacterial induction of Snail1 contributes to blood-brain barrier disruption. J Clin Invest. 2015 Jun;125(6):2473-83. doi: 10.1172/JCI74159. Epub 2015 May 11.
  4. Smurthwaite CA, Williams W, et al. Genetic barcoding with fluorescent proteins for multiplexed applications. J Vis Exp. 2015 Apr 14;(98). doi: 10.3791/52452.
  5. Stolp ZD, Smurthwaite CA, et al. A Multiplexed Cell-Based Assay for the Identification of Modulators of Pre-Membrane Processing as a Target against Dengue Virus. J Biomol Screen. 2015 Jun;20(5):616-26. doi: 10.1177/1087057115571247. Epub 2015 Feb 27.
  6. Quistad SD, Stotland A, et al. Evolution of TNF-induced apoptosis reveals 550 My of functional conservation. Proc Natl Acad Sci U S A. 2014 Jul 1;111(26):9567-72. doi: 10.1073/pnas.1405912111. Epub 2014 Jun 9.
  7. Robinson SM, Tsueng G, et al. Coxsackievirus B exits the host cell in shed microvesicles displaying autophagosomal markers. PLoS Pathog. 2014 Apr 10;10(4):e1004045. doi: 10.1371/journal.ppat.1004045. eCollection 2014 Apr.
  8. Smurthwaite CA, Hilton BJ, et al. Fluorescent genetic barcoding in mammalian cells for enhanced multiplexing capabilities in flow cytometry. Cytometry A. 2014 Jan;85(1):105-13. doi: 10.1002/cyto.a.22406. Epub 2013 Oct 29.
  9. Hernandez G, Thornton C, et al. MitoTimer: a novel tool for monitoring mitochondrial turnover. Autophagy. 2013 Nov 1;9(11):1852-61. doi: 10.4161/auto.26501. Epub 2013 Oct 11.
  10. Gros G, Martinez L, et al. Modular construction of quaternary hemiaminal-based inhibitor candidates and their in cellulo assessment with HIV-1 protease. Bioorg Med Chem. 2013 Sep 1;21(17):5407-13. doi: 10.1016/j.bmc.2013.06.018. Epub 2013 Jun 14.
  11. Stolp ZD, Stotland A, et al. A Novel Two-Tag System for Monitoring Transport and Cleavage through the Classical Secretory Pathway – Adaptation to HIV Envelope Processing. PLoS One. 2013 Jun 19;8(6):e68835. doi: 10.1371/journal.pone.0068835. Print 2013.
  12. Barr JJ, Auro R, et al. Bacteriophage adhering to mucus provide a non-host-derived immunity. Proc Natl Acad Sci U S A. 2013 Jun 25;110(26):10771-6. doi: 10.1073/pnas.1305923110. Epub 2013 May 20.
  13. Rajakuberan C, Hilton BJ, Wolkowicz R. Protocol for a mammalian cell-based assay for monitoring the HIV-1 protease activity. Methods Mol Biol. 2012;903:393-405. doi: 10.1007/978-1-61779-937-2_27.
  14. Stotland A, Pruitt L, et al. Purification of the COP9 signalosome complex and binding partners from human T cells. OMICS. 2012 Jun;16(6):312-9. doi: 10.1089/omi.2011.0158. Epub 2012 Mar 13.
  15. Hilton BJ, Wolkowicz R. An assay to monitor HIV-1 protease activity for the identification of novel inhibitors in T-cells. PLoS One. 2010 Jun 3;5(6):e10940. doi: 10.1371/journal.pone.0010940.
  16. Belmont PJ, Chen WJ, et al. Roles for endoplasmic reticulum-associated degradation and the novel endoplasmic reticulum stress response gene Derlin-3 in the ischemic heart. Circ Res. 2010 Feb 5;106(2):307-16. doi: 10.1161/CIRCRESAHA.109.203901. Epub 2009 Nov 25.
  17. Wolkowicz R, Schaechter M. What makes a virus a virus? Nat Rev Microbiol. 2008 Aug;6(8):643; author reply 643. doi: 10.1038/nrmicro1858-c1.
  18. Bristow CL, Wolkowicz R, et al. NF-kappaB signaling, elastase localization, and phagocytosis differ in HIV-1 permissive and nonpermissive U937 clones. J Immunol. 2008 Jan 1;180(1):492-9.
  19. Matthew R, Banjevic M, et al. Use of the l1 norm for selection of sparse parameter sets that accurately predict drug response phenotype from viral genetic sequences. AMIA Annu Symp Proc. 2005:505-9.
  20. Rabinowitz M, Myers L, et al. Accurate prediction of HIV-1 drug response from the reverse transcriptase and protease amino acid sequences using sparse models created by convex optimization. Bioinformatics. 2006 Mar 1;22(5):541-9. Epub 2005 Dec 20.
  21. Wolkowicz R, Nolan GP. Gene therapy progress and prospects: novel gene therapy approaches for AIDS. Gene Ther. 2005 Mar;12(6):467-76.
  22. Wolkowicz R, Jager GC, Nolan GP. A random peptide library fused to CCR5 for selection of mimetopes expressed on the mammalian cell surface via retroviral vectors. J Biol Chem. 2005 Apr 15;280(15):15195-201. Epub 2005 Jan 18.
  23. Wolkowicz R, Nolan GP, Curran MA. Lentiviral vectors for the delivery of DNA into mammalian cells. Methods Mol Biol. 2004;246:391-411.
  24. Hale MB, Nolan GP, Wolkowicz R. Oligonucleotide-directed site-specific integration of high complexity libraries into ssDNA templates. Nucleic Acids Res. 2004 Jan 29;32(2):e22.
  25. Wolkowicz R, Nolan GP. Retroviral technology–applications for expressed peptide libraries. Front Biosci. 2003 May 1;8:d603-19. Review.
  26. Shakked Z, Yavnilovitch M, et al. DNA binding and 3′-5′ exonuclease activity in the murine alternatively-spliced p53 protein. Oncogene. 2002 Aug 1;21(33):5117-26.
  27. Herkel J, Erez-Alon N, et al. Systemic lupus erythematosus in mice, spontaneous and induced, is associated with autoimmunity to the C-terminal domain of p53 that recognizes damaged DNA. Eur J Immunol. 2000 Apr;30(4):977-84.
  28. Offer H, Wolkowicz R, et al. Direct involvement of p53 in the base excision repair pathway of the DNA repair machinery. FEBS Lett. 1999 May 7;450(3):197-204.
  29. Zhou X, Wang XW, et al. COOH-terminal domain of p53 modulates p53-mediated transcriptional transactivation, cell growth, and apoptosis. Cancer Res. 1999 Feb 15;59(4):843-8.
  30. Erez-Alon N, Herkel J, et al. Immunity to p53 induced by an idiotypic network of anti-p53 antibodies:generation of sequence-specific anti-DNA antibodies and protection from tumor metastasis. Cancer Res. 1998 Dec 1;58(23):5447-52.
  31. Wolkowicz R, Rotter V. The DNA binding regulatory domain of p53: see the C. Pathol Biol (Paris). 1997 Dec;45(10):785-96. Review.
  32. Li R, Sutphin PD, et al. Mutant p53 protein expression interferes with p53-independent apoptotic pathways. Oncogene. 1998 Jun 25;16(25):3269-77.
  33. Ruiz PJ, Wolkowicz R, et al. Idiotypic immunization induces immunity to mutated p53 and tumor rejection. Nat Med. 1998 Jun;4(6):710-2.
  34. Wolkowicz R, Peled A, et al. DNA-binding activity of wild-type p53 protein is mediated by the central part of the molecule and controlled by its C terminus. Cancer Detect Prev. 1998;22(1):1-13.
  35. Sthoeger Z, Evron E, et al. Anti-p53 autoantibodies in colon cancer patients. Ann N Y Acad Sci. 1997 Apr 5;815:496-8.
  36. Almog N, Li R, et al. The murine C’-terminally alternatively spliced form of p53 induces attenuated apoptosis in myeloid cells. Mol Cell Biol. 1997 Feb;17(2):713-22.
  37. Simons A, Melamed-Bessudo C, et al. PACT: cloning and characterization of a cellular p53 binding protein that interacts with Rb. Oncogene. 1997 Jan 16;14(2):145-55.
  38. Peled A, Schwartz D, et al. The role of p53 in the induction of polyploidity of myelomonocytic leukemic M1/2 cells. Oncogene.1996 Oct 17;13(8):1677-85.
  39. Wolkowicz R, Peled A, et al. Augmented DNA-binding activity of p53 protein encoded by a carboxyl-terminal alternatively spliced mRNA is blocked by p53 protein encoded by the regularly spliced form. Proc Natl Acad Sci U S A.1995 Jul 18;92(15):6842-6.
  40. Wolkowicz R, Elkind NB, et al. The DNA binding activity of wildtype p53 is modulated by blocking its various antigenic epitopes. Oncogene. 1995 Mar 16;10(6):1167-74.
  41. Rotter V, Aloni-Grinstein R, et al. Does wild-type p53 play a role innormal cell differentiation? Semin Cancer Biol. 1994 Jun;5(3):229-36.